StockData

Eton Pharmaceuticals vs Heron Therapeutics

ETON and HRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ETON and HRTX compare

Eton Pharmaceuticals is the larger company, worth 31 times as much as Heron Therapeutics ($1.8B against $58.9M).

Eton Pharmaceuticals grew revenue faster over the last twelve months (101% versus −4.4% for Heron Therapeutics).

Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.3% compared with −14.5% at Heron Therapeutics.

Eton Pharmaceuticals scores higher on the StockData Score (12 against 8 for Heron Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricETONHRTX
Size and price
Market cap$1.8B$58.9M
Share price$63.93$0.310
Change, 1 year266%−72.0%
Change, 5 years1302%−96.9%
Beta (5Y)0.881.79
Employees44128
StockData Score
Total score12 (better)8
Valuation score00
Growth score4 (better)1
Performance score4 (better)2
Health score45 (better)
Dividend score00
Valuation
P/E42.1×–
P/S13.0×0.4× (better)
P/B21.0×12.0× (better)
EV/EBITDA39.3×–
P/FCF47.8×–
FCF yield2.1% (better)−24.4%
Fair value$33.76–
Margin of safety−89.4%–
Growth
Revenue growth (TTM)101% (better)−4.4%
Revenue growth, 5Y average360% (better)11.8%
Profitability
Gross margin69.2%71.5% (better)
Operating margin28.8% (better)−5.7%
Net margin35.3% (better)−14.5%
FCF margin27.1% (better)−9.7%
Return on equity90.6% (better)−218%
Return on invested capital115%–
Financial health
Debt / equity0.27 (better)0.00
Net debt / EBITDA−0.71–
Current ratio1.792.33 (better)
Altman Z-score17.09 (better)−10.60
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions74.0%70.4%
Held by insiders5.6%21.6%
Insider net buying, 12 months−$35.0M–
Short interest, % of float7.4%22.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.